Evaluating clonidine response in children and adolescents with attention-deficit/hyperactivity disorder

Basit Öğe Kaydı
dc.contributor.authorKütük, Meryem Özlem
dc.contributor.authorGüler, Gülen
dc.contributor.authorTufan, Ali Evren
dc.contributor.authorSungur, Mehmet Ali
dc.contributor.authorTopal, Zehra
dc.contributor.authorKütük, Özgür
dc.date.accessioned2020-05-01T12:11:55Z
dc.date.available2020-05-01T12:11:55Z
dc.date.issued2018
dc.departmentDÜ, Tıp Fakültesi, Temel Tıp Bilimleri Bölümüen_US
dc.descriptionTopal, Zehra/0000-0001-8397-5636; KUTUK, OZGUR/0000-0001-9854-7220en_US
dc.descriptionWOS: 000454201400003en_US
dc.description.abstractAttention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder in childhood, which is generally treated with stimulant and non-stimulant medications. However, 10-30% of patients in clinical setting do not present with adequate response to initial stimulant treatment. Thereby, clonidine may be considered for those patients who have failed to respond to psychostimulant/atomoxetine monotherapy or as an augmentation for inadequate response/comorbidity. This observational study evaluated its effectiveness as a single drug in ADHD cases unresponsive to previous treatment trials. Seventeen ADHD cases that were non-responders to stimulant, non-stimulant and combination therapy for the primary symptoms of ADHD were included in the study. Four cases dropped out before follow up, leaving thirteen cases who were administered immediate release clonidine treatment alone with a mean dose of 0.2 +/- 0.05 mg/day at baseline. The trial lasted for 12 weeks, and treatment outcomes were evaluated by the Turgay DSM-IV Based Child and Adolescent Behavior Disorders Screening and Rating Scale (T-DSM-IV-S) and the Clinical Global Impressions-Severity (CGI-S) and Improvement (CGI-I) scales. Mean age of the sample was 12.5 years (SD = 3.0) and eleven of the subjects had another comorbid psychopathology. Only two cases were evaluated as "very much improved", while another patient was judged to be "minimally improved" after 12 weeks of clonidine treatment. Attrition during follow-up was associated with higher median scores on the hyperactivity and impulsivity subscales (Mann-Whitney U test, p = 0.02). According to the T-DSM-IV-S, CGI-S, and CGI-I scales, clonidine treatment by itself had minimal benefits in this sample of treatment of refractory cases with ADHD evaluated at the study center. Clonidine is not available in Turkey pharmaceutical marketing system and patients' access to drug is limited. Our results provide first data regarding the use of clonidine in Turkish ADHD patients.en_US
dc.identifier.doi10.3934/medsci.2018.4.348en_US
dc.identifier.endpage356en_US
dc.identifier.issn2375-1576
dc.identifier.issue4en_US
dc.identifier.startpage348en_US
dc.identifier.urihttps://doi.org/10.3934/medsci.2018.4.348
dc.identifier.urihttps://hdl.handle.net/20.500.12684/6283
dc.identifier.volume5en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherAmer Inst Mathematical Sciences-Aimsen_US
dc.relation.ispartofAims Medical Scienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAlpha-2 adrenergic receptor agonisten_US
dc.subjectAttention-Deficit/Hyperactivity Disorderen_US
dc.subjectClonidineen_US
dc.titleEvaluating clonidine response in children and adolescents with attention-deficit/hyperactivity disorderen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
6283.pdf
Boyut:
291.58 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu